S1 guidelines for the diagnosis and

treatment of ichthyoses – update by Oji, V. et al.
1© 2017 The Authors | Journal compilation © Blackwell Verlag GmbH, Berlin | JDDG | 1610-0379/2017
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Guideline
DOI: 10.1111/ddg.13340
S1 guidelines for the diagnosis and 
treatment of ichthyoses – update
Vinzenz Oji1, Marie-Luise Preil2, Barbara Kleinow3, Geske Wehr4, 
Judith Fischer5, Hans Christian Hennies6, Ingrid Hausser7, Dirk 
Breitkreutz8, Karin Aufenvenne9, Karola Stieler10, Illiana Tantche-
va-Poór11, Stefan Weidinger12, Steffen Emmert13, Henning Hamm14, 
Ana Maria Perusquia-Ortiz15, Irina Zaraeva1, Anja Diem16, Kathrin 
Giehl17, Regina Fölster-Holst12, Kirstin Kiekbusch18, Peter Höger19, 
Hagen Ott20, Heiko Traupe1
(1) Department of Dermatology – General Dermatology and Venereology, Münster 
University Medical Center, Von-Esmarch-Str. 58, 48149, Münster, Germany
(2) Dermatology Practice am Färberturm, Weißenburger Str. 19, 91710, Gunzenhau-
sen, Germany
(3) Raiffeisenstr. 15, 57482, Wenden OT Dörnscheid, Germany
(4) In den Dellen 21, 51515, Kürten-Hufe, Germany
(5) Institute for Human Genetics, Freiburg University Hospital, Breisacher Str. 33,  
D-79106, Freiburg i. Br., Germany
(6) Department of Dermatogenetics, University of Cologne, Weyertal 115b, 50931, 
Cologne, Germany
(7) Pathology IPH, EM Laboratory, Heidelberg University Hospital, INF 224, 69120, 
Heidelberg, Germany
(8) German Society for Cell Biology/German Cancer Research Center Heidelberg & 
Mannheim University of Applied Sciences, Im Fuchsloch 18, 69221, Dossenheim/bei 
Heidelberg, Germany
(9) IUF – Leibniz Research Institute for Environmental Medicine, Auf’m Hennekamp 
50, 40225, Düsseldorf, Germany
(10) Charité Berlin – University Medicine, Mitte Campus, Outpatient Clinic for Pedia-
tric Dermatology at Mitte Campus, Department of Dermatology, Venereology, and 
Allergology, Schumannstr. 20–21, 10117, Berlin, Germany
(11) Department of Dermatology, Cologne University Hospital, Kerpener Str. 62, 
50937, Cologne, Germany
(12) Department of Dermatology, Venereology and Allergology, University Hospital 
Schleswig-Holstein, Kiel Campus, Schittenhelmstr. 7, 24105, Kiel, Germany
(13) Department of Dermatology and Venereology, University Medicine Rostock, 
Strempelstr. 13, 18057, Rostock, Germany
(14) Department of Dermatology, Venereology, and Allergology, Würzburg Universi-
ty Hospital, Josef-Schneider-Str. 2, 97080, Würzburg, Germany
(15) Dermatology Practice Tentrup/Köster-Tentrup, Weberstr. 40, 49477, Ibbenbüren, 
Germany
Q1
ddg13340_eng.indd   1 08/09/17   9:56 PM
Guidelines
2 © 2017 The Authors | Journal compilation © Blackwell Verlag GmbH, Berlin | JDDG | 1610-0379/2017
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
1 Definition, classification,  
and objective
Ichthyoses comprise a heterogeneous group of genetic disea-
ses characterized by abnormal keratinization that involves 
the entire skin [1, 2]. Primary clinical symptoms include thi-
ckening of the stratum corneum, xerosis, and visible scaling. 
Furthermore, the ability to perspire is frequently markedly 
decreased, which can lead to hyperthermia and eventually 
circulatory collapse [2]. Two main groups can be distingu-
ished [2]:
 (Nonsyndromic) ichthyoses only affecting the skin 
(ichthyosis vulgaris, autosomal recessive congenital 
ichthyosis, epidermolytic ichthyosis, and others)
 Ichthyosis syndromes that are characterized by the in-
volvement of other organ systems in addition to the skin 
(Chanarin-Dorfman syndrome, Comèl-Netherton syn-
drome, KID syndrome, Refsum’s disease, Sjögren-Lars-
son syndrome [SLS], trichothiodystrophy, and others)
Differentiating common forms of ichthyosis (ichthyo-
sis vulgaris, X-linked recessive ichthyosis) from rare 
ichthyosis variants, which are frequently already present at 
birth, is the key to adequate diagnostic management. Cli-
nical manifestations of these congenital ichthyoses include 
collodion baby or congenital ichthyosiform erythroderma 
(CIE). Today, the various forms of erythrokeratodermia 
are classified as ichthyoses [2]. There is some overlap with 
palmoplantar keratoses, for example in the case of loricrin 
keratoderma.
Given that hereditary ichthyoses are genetic disorders, 
no cure is possible to date. There are, however, options to 
mitigate their symptoms. The diagnostic workup has a po-
sitive impact with respect to how individuals cope with the 
disease; it is perceived as concrete support by patients and 
their families. The present guidelines pursue the following 
objectives:
 Diagnostic clues in the workup of ichthyoses
 Summary of the options available for symptomatic tre-
atment taking into account current literature and expert 
consensus
 Information on clinical/diagnostic centers in Germany
 Given the rarity and complexity of ichthyosis disorders 
and syndromes, the guidelines focus on the fundamen-
tals of the general diagnostic workup and treatment of 
ichthyoses. Peculiarities of important individual ichthyo-
sis variants are highlighted.
(16) EB House Austria, Department of Dermatology, Salzburg Medical Center, 
Paracelsus Private Medical University, Müllner Hauptstr. 48, A-5020, Salzburg, Austria
(17) Center for Rare and Genetic Skin Diseases, Department of Dermatology and 
Allergology, LMU Munich, Frauenlobstr. 9–11, 80337, Munich, Germany
(18) Kirstin Kiekbusch, Straße der Einheit 5d, 15749, Mittenwalde/Brusendorf, Germany
(19) Center for Pediatric and Adolescent Medicine, Liliencronstr. 130, 22149, 
Hamburg, Germany
(20) Department of Pediatric Dermatology and Allergology, Center for Pediatric 
and Adolescent Medicine, Children’s Hospital Auf der Bult, Janusz-Korczak-Allee 12, 
30173, Hanover, Germany.
Summary
Ichthyoses are a group of rare genetic skin disorders that pose numerous clinical 
challenges, in particular with respect to the correct diagnosis and appropriate ma-
nagement. The present update of the German ichthyosis guidelines addresses recent 
diagnostic advances that have resulted in the Sorèze consensus classification. In this 
context, we provide an updated diagnostic algorithm, taking into account clinical fea-
tures as well as the molecular genetic basis of these disorders. Moreover, we highlight 
current therapeutic approaches such as psychosocial support, balneotherapy, me-
chanical keratolysis, topical therapy, and systemic retinoid therapy. General aspects 
such as the indication for physical therapy, ergotherapy, or genetic counseling are 
also discussed. The present update was consented by an interdisciplinary consensus 
conference that included dermatologists, pediatricians, human geneticists, and na-
tural scientists as well as representatives of the German patient support organization 
Selbsthilfe Ichthyose e. V.
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1.1 Nonsyndromic ichthyoses
Table 1 lists important nonsyndromic ichthyoses, their mode 
of inheritance, and the genes associated with the disorder (to 
the extent known to date).
1.2 Syndromic ichthyoses
A list of ichthyosis syndromes can be found in Table 2. The 
skin changes associated with syndromic ichthyoses are not 
always of primary importance. Here, the other prominent 
clinical features listed are meant to serve as diagnostic clues.
1.3 Diagnostic criteria for differentiation
Apart from clinical criteria, ichthyoses can be classified using 
the following diagnostic methods [2–4]:
 Histology and immunohistochemistry [5],
 Ultrastructural/electron microscopy [6, 7],
 Molecular genetic studies [2, 4, 8].
2 Etiology
Common to all ichthyoses is the occurrence of genetically 
determined epidermal changes, resulting in decreased wa-
ter-binding capacity and impairment of the skin’s barrier 
function [9].
Most forms histologically classified as non-epider-
molytic are characterized by impaired terminal epidermal 
differentiation, which primarily affects the granular and 
corneal layers. The primary pathogenetic change associated 
with classic epidermolytic ichthyoses is located in the stra-
tum spinosum (abnormal cytoskeleton caused by mutations 
in keratins 1, 2 or 10, which are expressed depending on 
differentiation), and explains their tendency for skin fragili-
ty, especially among newborns. Some ichthyoses marked by 
pronounced inflammation are associated with defects in cell 
adhesion proteins (connexinopathies, corneodesmosin defi-
ciency, and others) or of the epidermal protease equilibrium 
(for example, LEKTI deficiency in case of Netherton syndro-
me). For some entities, the exact pathomechanism of the skin 
changes has to date not been elucidated (DNA repair gene 
defects) [10, 11].
3 Epidemiology
The most common forms of ichthyosis are ichthyosis vulgaris 
(prevalence of 1 in 100–1 in 250), X-linked recessive ichthyo-
sis (prevalence of 1 in 4,000) [8], autosomal recessive conge-
nital ichthyosis (prevalence of 1 in 60,000–1 in 200,000) [12] 
and epidermolytic ichthyoses (prevalence of 1 in 200,000–1 in 
500,000) [3]. While this makes X-linked recessive ichthyosis 
a rare disease according to EU classification (prevalence lower 
than 1 in 2,000), it is still considered to be part of the “common” 
disease variants within the spectrum of ichthyoses. All other 
forms must ultimately be considered to be exceedingly rare.
4 Diagnosis
4.1 History and clinical findings
A standardized history and clinical findings form is provided 
by the Network for Ichthyoses and Related Keratinization 
Disorders (NIRK)/Münster Center for Rare Diseases (http://
www.netzwerk-ichthyose.de/index.php?id = 23). It includes 
the following questions:
 Initial manifestation of ichthyosis: manifestation at 
birth, course and length of pregnancy, polyhydramnion, 
birth complications, clinical findings at birth, collodion 
membrane, blistering, exfoliation, ectropion, eclabium, 
erythroderma, ear deformities, joint contractures, infec-
tions, other extracutaneous symptoms (see below)
 Family history, pedigree, question about consanguinity
 Clinical course after birth, during childhood/adulthood, 
seasonal variability
 Current clinical findings: light/dark brown/black, fine, 
coarse lamellar/plate-like scaling; mild/moderate/seve-
re erythema; pattern of involvement (generalized/loca-
lized); involvement of the antecubital/popliteal fossae; 
palmoplantar hyperlinearity and/or keratosis; blistering; 
exfoliation; keratotic lichenification; signs of impaired 
ability to perspire/impaired thermoregulation with ten-
dency for hyperthermia; photosensitivity
 Skin appendages: alopecia, hypotrichosis, hair shaft 
anomalies, nail anomalies
 Extracutaneous symptoms: visual/ocular/hearing impair-
ment; joint contractures; skeletal anomalies; tooth anoma-
lies; visceral, neurological, motor impairment; mental re-
tardation; hepatomegaly (transaminases); cryptorchidism, 
vitamin D deficiency, metabolic disorders (Jordan’s ano-
maly), type I hypersensitivities (CBC with differential, IgE)
4.2 Clinical (differential) diagnostic clues
Establishing the correct clinical diagnosis requires answers 
to the following questions:
1. Has the ichthyosis been present since birth? Differentia-
tion between rare congenital forms of ichthyosis, which 
are present at birth or shortly thereafter, and common 
ichthyosis forms that tend to manifest themselves at a 
later point in time (ichthyosis vulgaris).
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Table 1 Nonsyndromic ichthyoses.
Disorder Mode of inheritance Gene(s)
Common ichthyoses
Ichthyosis vulgaris (IV) [146700] Autosomal semi-dominant FLG
X-linked recessive ichthyosis (XRI)
Nonsyndromic presentation [308100] XR STS
Autosomal recessive congenital ichthyosis (ARCI]
Harlequin ichthyosis
ARCI4B [242500] AR ABCA12
Lamellar ichthyosis (LI) / congenital ichthyosiform erythroderma (CIE)
ARCI1 [242300] TGM1
ARCI2 [242100] ALOX12B
ARCI3 [606545] ALOXE3
ARCI4A [601277] ABCA12
ARCI5 [604777] CYP4F22
ARCI6 [612281] NIPAL4
ARCI8 [613943] AR LIPN
ARCI9 [615023] CERS3
ARCI10 [615024] PNPLA1
ARCI11 [602400] ST14
ARCI12 [617320] CASP14
Self-improving congenital ichthyosis (SICI)
ARCI1 [242300] TGM1
ARCI2 [242100] AR ALOX12B
ARCI3 [606545] ALOXE3
Bathing suit ichthyosis (BSI)
ARCI1 [242300] AR TGM1
Keratinopathic ichthyosis (KPI)
Epidermolytic ichthyosis (EI) [113800] AD KRT1 / KRT10
Superficial epidermolytic ichthyosis (SEI) [146800] AD KRT2
KPI variants
Annular epidermolytic ichthyosis (AEI) [607602] AD KRT1 / KRT10
Ichthyosis Curth-Macklin (ICM) [146590] AD KRT1
Autosomal recessive epidermolytic ichthyosis (AREI) [113800] AR KRT10
Congenital reticular ichthyosiform erythroderma (CRIE) [609165] AD KRT10 / KRT1
Epidermolytic nevi [113800] Postzygotic mosaicism KRT1 / KRT10
Other nonsyndromic ichthyoses
Loricrin keratoderma (LK) [604117] AD LOR
Erythrokeratodermia variabilis (EKV) [133200] AD GJB3/GJB4
Peeling skin disease (PSD) [270300] AR CDSN
Keratosis linearis with ichthyosis congenita and sclerosing keratoderma 
(KLICK) [601952]
AR POMP
Modified from Oji et al. 2010 [2].
OMIM number in [] (see http://www.ncbi.nlm.nih.gov/omim).
Q2
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2. Is there pronounced erythroderma? As a symptom, ery-
throderma is nonspecific; it does, however, point in the 
direction of a rare congenital form of ichthyosis (examp-
le: congenital ichthyosiform erythroderma).
3. Is/has the ichthyosis ever been associated with blisters? 
Important clue as to the presence of keratinopathic 
ichthyosis.
4. Are there associated symptoms? Further symptom-ori-
ented workup to rule out a syndromic ichthyosis variant.
Figures 1 and 2 present organizational charts with respect to 
differential diagnostic considerations.
4.3 Laboratory studies
In principle, the objective should be to establish the diagnosis 
as early as possible, in accordance with the parents. As the 
various tests necessary are associated with more or less inva-
sive procedures (skin biopsy and/or drawing of blood), the 
time of the diagnostic workup must be based on the patient’s 
clinical condition.
We recommend performing several diagnostic tests at 
the same time in order to avoid having to take multiple biop-
sies in more than one session. In this context, prior consul-
tation with centers specialized in ichthyoses is advisable. 
Table 2 Syndromic ichthyoses.
Disorder Mode of inheritance Gene(s)
X-linked ichthyosis syndrome
X-linked recessive ichthyosis (XRI) syndromic forms [308700, 300500, 
300533]
XR STS (and others)
Ichthyosis follicularis with alopecia and photophobia (IFAP) syndrome 
[308205]
XR MBTPS2
Conradi-Hunermann-Happle syndrome [302960] (CDPX2) XD EBP
Autosomal recessive ichthyosis syndromes with prominent hair abnormalities
Netherton syndrome (NTS) [256500] AR SPINK5
Ichthyosis-hypotrichosis syndrome (IHS) [610765] (see ARCI11 in Table 1) AR ST14
Trichothiodystrophy (TTD) AR ERCC2/XPD
[601675] ERCC3/XPB
GTF2H5/TTDA
Trichothiodystrophy (non-congenital forms) AR C7Orf11/TTDN1
[275550, 211390, 601675]
Autosomal recessive ichthyosis syndromes with prominent neurological symptoms
Sjögren-Larsson syndrome (SLS) [270200] AR ALDH3A2
Refsum’s disease (HMSN4) [266500] AR PHYH/PEX7
Mental retardation, enteropathy, deafness, neuropathy, ichthyosis, 
keratoderma (MEDNIK) syndrome [609313]
AR AP1S1
Autosomal recessive ichthyosis syndromes with fatal outcome
Type 2 Gaucher disease type 2 [230900] AR GBA
Multiple sulfatase deficiency (MSD) [272200] AR SUMF1
Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar 
keratoderma (CEDNIK) syndrome
AR SNAP29
[609528]
Arthrogryposis, renal dysfunction, cholestasis (ARC) syndrome [208085] AR VPS33B
Other syndromic ichthyoses
Keratitis-ichthyosis-deafness (KID) syndrome [602450, 148210] AD GJB2 (GJB6)
Neutral lipid storage disease with ichthyosis [275630] AR ABHD5
Ichthyosis prematurity syndrome (IPS) [608649] AR SLC27A4
Modified from Oji et al. 2010 [2].
OMIM number in [] (see http://www.ncbi.nlm.nih.gov/omim).
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(Examples are listed in Table S1 [online Supporting Informa-
tion]). Further information on the various techniques can be 
obtained through the aforementioned treatment centers. The 
following diagnostic laboratory tests are available:
 Histology and hair analyses: morphological charac-
teristics of ichthyosis vulgaris, epidermolytic ichthyo-
sis, loricrin keratoderma, ichthyosis follicularis with 
alopecia and photophobia (IFAP syndrome), X-linked 
chondrodysplasia punctata type 2 (CDPX2), keratosis 
linearis with ichthyosis congenita and sclerosing kera-
toderma (KLICK), peeling skin disease. In combination 
with immunohistology: specific antigen mapping for 
ichthyosis vulgaris (filaggrin), Comèl-Netherton syn-
drome (LEKTI), peeling skin disease (CDSN). In case 
of Comèl-Netherton syndrome (trichorrhexis invagina-
ta) and trichothiodystrophy (tiger-stripe pattern using a 
polarization filter, respectively low amount of cysteine), 
hair analyses provide key diagnostic clues.
 Electron microscopy (criteria according to [6]: very 
specific for the assessment of ichthyosis vulgaris, epider-
molytic ichthyosis, harlequin ichthyosis (HI), KLICK, lo-
ricrin keratoderma and ichthyosis prematurity syndrome. 
Narrowing down of specific autosomal recessive congeni-
tal (ARCI) ichthyosis forms: TGM1, PNPLA1, NIPAL4
 Measurement of functional activity: fast frozen skin 
biopsy: in situ procedure to measure enzyme activity in 
collodion babies and/or ARCI (screening for transgluta-
minase-1 deficiency)
 EDTA blood: steroid sulfatase activity measurement in 
case of suspected X-linked recessive ichthyosis (XRI) or 
metabolite screening
 Molecular genetic studies: highly important for rare and 
severe forms of ichthyosis
4.4 Involvement of different medical specialties
The diagnosis and management of ichthyoses require an 
interdisciplinary approach [13, 14]. Neonatal ichthyoses 
necessitate close cooperation between neonatologists/pedi-
atricians and dermatologists. In addition, timely evaluation 
by ophthalmologists and ENT specialists are indicated [15]. 
Depending on the specific disorder, an orthopedic and/or 
gastroenterological workup should also be carried out. Some 
children with ichthyosis require regular ergotherapy and/or 
physical therapy and benefit from sojourns at health resorts. 
Q4
Figure 1 Diagnostic workup of common ichthyoses: patients with ichthyosis vulgaris (IV) or X-linked recessive ichthyosis (XRI) 
present in early childhood or even as adults as the onset of skin lesions is usually after birth in the first year of life. Apart from 
acquired ichthyosis, important differential diagnoses of “late-onset” ichthyosis include Refsum’s disease or a mild form of auto-
somal recessive congenital ichthyosis. The figure depicts a patient with ichthyosis vulgaris. Abbr.: STS, steroid sulfatase; FISH, 
fluorescence in situ hybridization; FLG, filaggrin.
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With respect to genetic counseling, parents should go to a 
genetic counseling office. Another option is to consult recog-
nized ichthyosis experts in preparation for or commissioning 
of molecular genetic tests (specialized genetic counseling).
5 Treatment
5.1 Comments on the data available
With regard to the treatment of ichthyoses, there are only 
few methodologically high-quality studies available [12]; 
thus, the level of evidence primarily corresponds to “expert 
opinions” by specialists working at treatment centers with 
longstanding experience [3, 13, 16–22]. The development of 
novel forms of treatment is hampered by the circumstance 
that – given the rarity of severe ichthyoses in particular – 
conducting controlled studies proves to be exceedingly dif-
ficult, for example due to the long distances patients have to 
travel to get to the study centers. In Germany, the Network 
for Ichthyoses and Related Keratinization Disorders (NIRK), 
which manages a central patients registry, was initiated in 
2004 (www.netzwerk-ichthyose.de).
5.2 General objectives of symptomatic 
treatment options
Although there is currently no cure for genetic keratinization 
disorders, skin condition and quality of life can be signifi-
cantly improved through optimized use of the wide range of 
therapeutic options available for the treatment of ichthyoses.
General therapeutic goals include the removal of hyper-
keratosis and scales, making the skin smoother, facilitating 
the healing of rhagades, and preventing their occurrence [17]. 
These objectives can be achieved by hydrating the stratum 
corneum and minimizing the formation of hyperkeratosis. 
The following forms of treatment have become established 
practice and may be employed separately or in combinati-
on: balneotherapy, topical therapy with ointments, systemic 
Figure 2 Differential diagnostic considerations in congenital ichthyoses: whenever a neonate shows features of “collodion 
baby” or congenital ichthyosiform erythroderma, all differential diagnoses of congenital ichthyosis, including early manifesta-
tion of XRI, need to be considered. Some clinical features may provide clues as to specific nonsyndromic or syndromic types 
of ichthyosis. Crucial clues can frequently be gathered by appropriate photodocumentation and subsequent evaluation by an 
expert. The photograph shows a collodion baby. Possible diagnoses are boxed in red. Abbr.: ARCI, autosomal recessive conge-
nital ichthyosis; CDPX2, X-linked chondrodysplasia punctata type 2; CIE, congenital ichthyosiform erythroderma; HI, harlequin 
ichthyosis; IPS, ichthyosis prematurity syndrome; IV, ichthyosis vulgaris; KID, keratitis-ichthyosis-deafness syndrome; KRT, kera-
tin; LI, lamellar ichthyosis; MEDNIK, mental retardation-enteropathy-deafness-neuropathy-ichthyosis-keratoderma syndrome; 
NISCH, neonatal ichthyosis-sclerosing cholangitis syndrome; NTS, Comèl-Netherton syndrome; PSD, peeling skin disease; SLS, 
Sjögren-Larsson syndrome; TTD, trichothiodystrophy; XRI, X-linked recessive ichthyosis.
Q5
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treatment. It should be pointed out that some patients, for 
example those with epidermolytic ichthyosis or Netherton 
syndrome, also require appropriate dressing material.
Specific information on certain forms of ichthyosis can 
be found in chapter 7 of the long version of these guidelines 
(online supporting information).
5.3 Psychosocial and emotional support
For parents, the diagnosis of ichthyosis means giving up their 
notion of having a healthy child. The extreme emotional dis-
tress thus caused must be cushioned by the services offered 
by contact persons at the hospital and subsequently by soci-
al pedagogues, psychologists, psychotherapists, and family 
midwives [18, 23].
Grief and feelings of guilt on the part of the parents have 
to be addressed in order to achieve the emotional stability 
necessary to facilitate day-to-day life with an incurably and 
chronically ill child, both with respect to the time-consuming 
care and in terms of handling their social environment.
Contact to support organizations such as Selbsthilfe 
Ichthyose e. V. can provide critical relief to affected families 
with regard to psychosocial and practical issues. At Selbst-
hilfe Ichthyose e. V., they can find trained contact persons – 
some specialized in different fields – not only for issues related 
to care but also to everyday life with ichthyosis in all its facets.
5.4 Physical therapy, ergotherapy,  
and rehabilitation measures
Depending on the age of those affected and particularly in the 
case of children, regular physical therapy, possibly in combi-
nation with ergotherapy, is frequently indicated. Tightening 
of the skin in the area of the joints affects their free range of 
motion. In the case of severe non-syndromic ichthyoses (inclu-
ding harlequin ichthyosis, lamellar ichthyosis, epidermolytic 
ichthyosis), the prevention of contractures is imperative; in 
case of syndromic ichthyoses, such as Sjögren-Larsson syn-
drome, physical therapy may lead to clinical improvement.
In this context and with regard to general health aspects, 
we recommend offering rehabilitation measures for ichthyo-
sis patients at specialized rehabilitation centers that also pro-
vide facilities for balneotherapy. Insurance companies should 
allow affected patients to stay at those rehabilitation centers 
that have sufficient experience in the management of ichthyo-
sis, and where it is more likely to meet other patients afflicted 
with this rare disorder (psychosocial and emotional support).
5.5 Balneotherapy
Affected patients (Selbsthilfe Ichthyose e. V.) and treating 
physicians (from rehabilitation centers, for example) have 
Q6
accumulated a great deal of experience showing the effec-
tiveness of balneotherapy. Unfortunately, there is a lack of 
methodologically high-quality studies on balneotherapy for 
ichthyosis [21, 24].
The concern that the protective lipid barrier of the skin 
might be “overstrained” by frequent bathing bears no rele-
vance in the context of ichthyosis treatment. The very oppo-
site is true: intensive bath therapy is very beneficial in severe 
ichthyosis cases. Regular bathing – once or several times a 
day – cleanses the skin, removes the residue of ointments, 
and loosens scales. At the same time, the skin is hydrated. 
Furthermore, hyperkeratoses are softened, which facilitates 
their subsequent mechanical removal. Bathing in plain water 
(or using a commercially available foam bath) usually fulfills 
the various functions – cleansing, hydration, and softening 
of the keratoses – sufficiently well. In the case of lamellar 
ichthyosis, however, bath additives with a neutral pH hardly 
have any effects (see section 200; keratolytic bath additives). 
In preparation for bathing in the tub, a brief (5–15 minu-
tes) temperature-controlled steam bath or steam shower is 
recommended; such pretreatment is meant to thoroughly hy-
drate the skin and soften the hyperkeratoses [17, 18]. In this 
context, it is important to keep in mind that most individuals 
affected have the tendency to develop hyperthermia due to 
their decreased ability to perspire (which explains the advan-
tage of a cooler steam sauna) [17, 21].
5.5.1 Plain bath additives
Examples of emollient bath additives include oils (which re-
quire an additional emulsifying agent, though), spreading 
oils and a large number of less common “secret recipes”, in-
cluding bran creams, sugar beet syrup/molasses, and whey. 
The indication for the various bath additives is based on what 
is predominantly required: lipid replacement or keratolysis 
[17]. By contrast, oils – by themselves – frequently do not 
have any keratolytic effects. They do, however, require grea-
ter effort in cleaning the bathtub, and are associated with the 
risk of slipping (and falling). While they may also be directly 
applied to the skin after the bath, their effects are only short-
lived if a towel is subsequently used for drying.
5.5.2 Salt
Bathing in water containing regular sodium chloride or salt 
from the Dead Sea promotes hydration and keratolysis. Howe-
ver, patients with erythrodermic ichthyoses, Comèl-Nether-
ton syndrome, and ichthyoses with erosive areas, may experi-
ence uncomfortable burning sensations, which argues against 
this therapeutic option. With most other forms of ichthyosis, 
the burning sensation ceases once patients have gotten used 
to the treatment. The salt concentration can then be increased 
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from 1 % up to 8 % without any complications. Given that 
higher salt concentrations cause corrosion of the plumbing 
system, this form of treatment is generally reserved for in-
patient facilities or office-based dermatologists [17]. The salt 
concentration used for children should not exceed 3–4 %.
5.5.3 Keratolytic bath additives
The following bath additives have been shown to have kera-
tolytic effects: sodium hydrogen carbonate (pharmacy-grade 
sodium bicarbonate powder or in the form of baking soda 
[available from wholesale bakery stores]), wheat starch 
(amylum tritici), rice starch (amylum oryzae) and corn starch 
(amylum maydis).
The increase in pH associated with the (alkaline) sodium 
hydrogen carbonate causes a softening and loosening of the 
hyperkeratosis – presumably through the increased activity 
of serine proteases. For adults, approximately 6 g of sodium 
bicarbonate per liter of bathwater – i.e. 3–4 handfuls (around 
400 g) of sodium bicarbonate per bathtub – is necessary to 
adequately promote keratolysis. We generally recommend 
this treatment only for patients ≥ 1 year of age; for infants/
toddlers, the concentration should be halved (approximately 
3 g per liter). To simplify matters, commercially available ba-
king soda can be used instead of sodium hydrogen carbonate 
[17, 18, 25].
5.6 Mechanical keratolysis
Following adequate softening of the keratoses in the bathtub 
(usually after 10–20 minutes) or immediately after pretre-
atment in the steam bath, various tools can be used to me-
chanically remove (with gentle pressure) the hyperkeratosis 
while repeatedly dousing the skin in the bath water. Suitable 
mechanical tools are commercially available. Tried and tes-
ted products include pumices or artificial stones, special “silk 
cloths from China”, “Moroccan or Turkish washing mittens” 
in various degrees of coarseness. Microfiber cloths in various 
qualities (available from drugstores or supermarkets) are use-
ful for sensitive areas [18].
While supplementary mechanical keratolysis is superior 
to treatment solely with topical keratolytic agents, it does re-
quire a sufficient amount of practice. The frequency of use 
depends on the clinical condition (between once a day and 
once a week). The average amount of time needed for who-
le-body treatment in a patient with (well-controlled) severe 
ichthyosis is approximately 60–90 minutes [17].
5.7 Topical agents
Following water contact and in particular immediately after 
balneotherapy, topical lipid replacement has to be ensured in 
Q7
order to maintain the hydration achieved by the bath. Additi-
onal keratolytic ingredients contained in the ointment act as 
a supplement to mechanical keratolysis, and can help coun-
teract the recurrence of rhagades.
Topical preparations should not just be applied after 
every shower/bath. In severe ichthyosis cases, it is recommen-
ded to apply cream to the entire skin at least once or twice a 
day. If necessary, individual sites may have to be re-treated 
several times a day. With regard to commercially available 
ready-to-use preparations, the same products can be used as 
in children with atopic dermatitis; ichthyosis patients, howe-
ver, tend to require an oilier base/formulation.
Given the higher rate of absorption and greater level of 
irritability in babies and infants, they should be treated with 
medication-free topical formulations [26]; the frequency of 
application in this patient group is roughly six to eight times 
daily [17, 21].
5.7.1 Urea
Urea was introduced into the treatment of ichthyosis by the 
Swedish physician Swanbeck in 1968 [27]. Considerable cli-
nical experience has been gained not only at treatment centers 
but also by European and US patient support organizations. 
There is, however, only one single randomized controlled stu-
dy in which the superiority of urea lotion (10 %) compared 
to the vehicle was demonstrated in ichthyosis patients [28].
Urea reduces epidermal proliferation, has barrier-rege-
nerating, antimicrobial, and keratolytic effects, smoothens 
the skin, and facilitates the penetration of other active ingre-
dients (depending on the base used). Extemporaneous formu-
lations and finished products containing urea (5–10 %) im-
prove the skin’s water-binding capacity and have keratolytic 
effects associated with low irritant potential. Urea can be 
combined with other active ingredients such as sodium chlo-
ride, lactic acid, or retinoic acid. The combination of urea 
5 % and glycerine 5 % has good keratolytic effects while, 
at the same time, showing less irritant potential. While the 
hydrating and protective effects do not improve with urea 
concentrations greater than beyond 5 %, higher concentra-
tions are required if the goal is to increase the keratolytic 
effects [29].
In children, urea should not be used in the first year 
of life. As regards inflammatory, erythematous, exfoliative 
ichthyoses, even low concentrations of urea frequently cause 
burning sensations. As the focus is less on keratolysis in these 
cases, one may resort to less irritant hydrating agents such as 
glycerine or dexpanthenol.
Based on the clinical presentation, it is frequently impos-
sible to determine with certainty whether urea will be tolera-
ted or not. Here, too, treatment therefore has to be based on 
individual tolerance.
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5.7.2 Glycerine
Glycerine promotes the exfoliation of corneocytes and acce-
lerates the breakdown of desmosomes by reducing desmo-
glein 1 [30]. It can be prescribed in any oil-in-water and am-
phiphilic base; concentrations of 5–10 % have proven useful 
(see section 230). The following officinal or new prescription 
formulary bases already contain glycerine 4.25 % and can 
serve as bases for formulations: non-ionic hydrophilic SR 
cream (NRF S.26) and lipophilic cream base (NRF 11.204) 
[29].
The use of glycerine as the only active ingredient has 
been shown to be particularly useful in ichthyosis vulgaris. In 
a double-blind randomized study, almost 70 % of all patients 
showed a response [31]; that percentage was lower in XRI 
(44 %) as well as congenital ichthyoses (43 %) [32].
5.7.3 Sodium chloride
Being hygroscopic, sodium chloride (NaCl) is a moisturizer. 
NaCl has a keratolytic effect at concentrations of 5–10 %; 
it is ideally used in a hydrophilic base. In extemporaneous 
formulations, NaCl is frequently present in crystalline struc-
tures of less than optimum quality, which is why such formu-
lations are not commonly used [1, 2].
5.7.4 Lactic acid
Lactic acid (acidum lacticum) is a moisturizer that is more 
hygroscopic than glycerine or urea. It reduces keratoses and 
is well tolerated at concentrations of 5 % in amphiphilic 
cream bases. Higher concentrations are more irritant and 
thus less recommendable [1, 2]. In extemporaneous formu-
lations, tolerance depends to a large degree on the lactic 
acid/sodium-lactate buffer [21]. In patients with severe 
barrier impairment, there is the theoretical risk of meta-
bolic acidosis; lactic acid should therefore not be used in 
newborns.
5.7.5 Polyethylene glycol (Macrogol 400)
An oil-in-water emulsifying agent, polyethylene glycol 
(PEG), specifically Macrogol 400, has a hygroscopic effect; 
following penetration, it is able to hydrate the corneal lay-
er. Given its hydrating effect without irritant potential, PEG 
(batch 400) shows mild keratolytic effectiveness. In amphi-
philic bases, it can be used at concentrations of 20–30% 
[1, 29]. One aspect still subject to debate is whether percuta-
neous PEG absorption has the potential of changing the os-
molarity of the blood. To date, it is unclear whether PEG 
should therefore not be used in the first and second year of 
life [33, 34].
5.7.6 Topical retinoids
Topical retinoids (tazarotene, retinoic acid, and tretinoin) 
are available as finished products (0.05–0.1 %) and in com-
bination products with urea (usually tretinoin 0.03 % with 
urea 12 %), and can be freely prescribed in extemporaneous 
formulations. Topical retinoids have very good antikeratotic 
effects but, due to their irritant potential, they are generally 
only suitable for localized keratinization disorders or recal-
citrant areas such as hands, feet, lower legs, and juxta-arti-
cular areas. In case of long-term treatment of large areas, 
their teratogenic potential must be observed. As a matter 
of precaution, neither pregnant women nor any woman of 
child-bearing age must be treated with topical retinoids if 
she is not using a reliable method of contraception [1, 29].
5.7.7 Salicylic acid (caution message)
Salicylic acid reduces intercellular cohesion and thus the 
thickness of the stratum corneum, and has a proteolytic ef-
fect. Salicylic acid penetrates the impaired skin barrier in 
patients with ichthyosis (especially if the pH is acidic), is 
absorbed, and can develop systemic effects. Salicylic acid 
leaves a deposit in the corneal layer that persists for up to 
13 days after the last application. If the skin barrier is im-
paired, said deposit formation is less pronounced; however, 
more of the substance is absorbed, which results in toxic 
levels following repeated application. Acute toxic effects 
have been observed in children. The addition of “only” 3 % 
salicylic acid has been reported to cause fatalities within 72 
hours due to metabolic acidosis, not only among newborns 
and babies but also among older children. Consequently, 
despite its good keratolytic properties, salicylic acid should 
not be used for whole-body treatment of ichthyosis. Whi-
le localized topical treatment of hard-to-treat areas in ol-
der patients is generally possible, we do not recommend it 
[1, 13, 17, 18, 29].
5.7.8 α-hydroxycarboxylic acid (fruit acids)
Our expert group is currently not (yet) able to evaluate the 
risk-benefit profile of α-hydroxy acids (AHA). (To date, our 
own experience is too limited.) Several recent case reports 
suggest that the addition of AHA in the treatment of ichthyo-
sis has a noticeable additive effect on creams containing urea 
(the effect corresponds to a mild AHA peeling). Affected 
individuals have reported that the frequency of this kind of 
topical treatment – following initially more frequent applica-
tion compared to previously used ointments – can be signi-
ficantly reduced over time. Due to their chemical properties, 
AHA are poorly suited for use in extemporaneous formula-
tions (oxidation on contact with air). Patients can purchase 
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AHA creams or lotions as finished products, for example, 
those offered on the Internet.
Evidence of the presumed benefit of AHA, especially 
for lamellar ichthyosis, should be obtained in the context of 
methodologically high-quality studies. In the case of inflam-
matory ichthyoses, the irritant potential (due to marked ke-
ratolytic effects) has to be taken into account; hence, based 
on current experience, the use of AHA is not recommended. 
As there is no safety data available, we advise against AHA 
being used in the first years of life.
5.7.9 Vitamin E
In creams, vitamin E 5 % is only suitable as additive if the 
following points are observed: vitamin E is not photostable, 
especially in aqueous solutions, which is why an antitoxidant 
such as butylated hydroxytoluene 0.05 % or α-tocopherol 
0.1 % should be added. Vitamin E has an optimum pH of 
4.5–5.
5.8 Topical preparations for specific sites
With respect to topical treatment, some site-specific peculia-
rities have to be observed [17]: on the scalp, preference should 
be given to water-soluble bases such as base cream DAC with 
keratolytic additives (urea 5–10 % and/or lactic acid 5 %). 
Therapeutic shampoos, with urea 5 % for example, are very 
useful. These shampoos should be left on the scalp for at least 
5–10 minutes; in mild cases, they have adequate keratolytic 
effects.
Facial skin care is key to mitigating an existing ectropi-
on. Treatment of the sensitive facial skin/eyelids should be 
done with glycerine-containing, low-dose keratolytic agents 
(urea of no more than 3 %) in an oil-in-water base in order to 
avoid irritation and folliculitis. In the majority of cases, sole 
emollient skin care without keratolytic agents is sufficient. 
Additives such as panthenol 5 % or vitamin E 5 % are suita-
ble in this context.
Every form of topical treatment can be enhanced by 
occlusive dressings (film dressings). In recalcitrant areas 
– for example, in case of dark, firmly adherent keratoses 
on the neck in patients with XRI, localized keratoses as-
sociated with erythrokeratoderma, or over the joints in 
individuals with ARCI/EI – occlusive dressings are highly 
effective [17].
5.9 Systemic treatment
Acitretin is the only agent approved for the systemic treat-
ment of ichthyoses. It inhibits keratinization and regulates 
cellular differentiation. With respect to the indication for 
its use, it is imperative to observe the summary of product 
characteristics and weigh the benefits and adverse effects, 
considering that the underlying genetic disorder requires li-
felong treatment. Apart from the contraindications (the sub-
stance’s teratogenicity in women), it is important to consider 
the patient’s compliance with regard to laboratory monito-
ring and, in case of long-term administration, X-ray monito-
ring). Even on systemic treatment, most ichthyoses will cont-
inue to require intensive, albeit somewhat simplified, topical 
treatment [22].
The improved ability to perspire can be a key reason in 
favor of using acitretin [35]. In general, systemic retinoids 
are more suitable for noninflammatory forms of ichthyo-
sis. They are thus well suited for the treatment of lamellar 
ichthyosis and XRI but also for superficial epidermolytic 
ichthyosis or KRT10-associated epidermolytic ichthyosis 
(care should be taken with regard to increased induction of 
blistering). With certain restrictions, acitretin treatment is 
also suitable for Netherton syndrome (increased tendency 
for dermatitis).
While the acitretin dose can initially be gradually increa-
sed, the long-term goal is to reach a maintenance dose that 
is as low as possible [22]. In adults, a dose of no more than 
1 mg/kg is adequate for the treatment of lamellar ichthyo-
sis; for superficial epidermolytic ichthyosis or in KRT10-as-
sociated epidermolytic ichthyosis, no more than 0.5 mg/kg. 
However, a lower dose is generally used for long-term treat-
ment (lamellar ichthyosis: 0.5 mg/kg: epidermolytic ichthyo-
sis (with keratin 10 mutation): 0.2 mg/kg). It should be no-
ted that retinoid therapy of epidermolytic ichthyosis (with 
KRT10 mutation) may be associated with marked disease ex-
acerbation. An acitretin dose of 0.5 mg/kg (maximum: 1 mg/
kg) is recommended for newborns with harlequin ichthyosis 
(see section 7.5). Long-term acitretin therapy should be avoi-
ded in children.
6 Genetic counseling
Following the diagnosis, ichthyosis patients and their relati-
ves should be advised to seek genetic counseling in order to 
provide detailed information with respect to heredity and the 
risk of recurrence [2, 17].
If mutations have been identified in the context of seve-
re forms of ichthyosis, counseling can address the possibili-
ty of prenatal diagnostic tests, for example, chorionic villus 
sampling (tenth to twelfth week of pregnancy) or amniocen-
tesis (starting in the fourteenth week of pregnancy). In princi-
ple, preimplantation diagnosis will in the future also become 
an option in select cases. However, this has to be discussed 
with the diagnostic laboratory and the other centers involved.
The addresses of local counseling offices can be obtained 
from the Professional Association of German Geneticists: 
http://www.bvdh.de/index.php.
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Comment on the methodology 
underlying the present guidelines
For methodology, conflicts of interest, and duration of vali-
dity, please refer to the long version of the guidelines online 
or to the AWMF website. This is an update of the guidelines 
published on April 17, 2008. Some passages were taken ver-
batim from the previous version.
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